Teladoc buys mental health company UpLift to help boost struggling BetterHelp unit

Teladoc buys mental health company UpLift to help boost struggling BetterHelp unit


Teladoc Health Inc. signage on the floor of the New York Stock Exchange on Dec. 31, 2024.

Michael Nagle | Bloomberg | Getty Images

Virtual care provider Teladoc Health, which has seen its market value plummet over the past five years, said Wednesday that it acquired mental health company UpLift for $30 million in cash.

Teladoc said the acquisition will help the company build out its struggling BetterHelp mental health segment. Revenue at BetterHelp declined 10% to about $250 million in 2024, and has faced challenges since the economy started reopening after the Covid pandemic.

UpLift, which offers virtual mental health therapy, psychiatry and medication management services, generated around $15 million in revenue last year, Teladoc said.  

“BetterHelp was founded to remove the traditional barriers to therapy and make mental health care more accessible to everyone,” BetterHelp President Fernando Madeira said in a statement. “We believe joining forces with UpLift will help us advance that mission — especially for those seeking to use their coverage benefits — while also driving topline revenue growth that will help sustain and expand our impact over time.”

Teladoc said the deal closed Wednesday, and UpLift will be factored into the BetterHelp segment going forward.

Don’t miss these insights from CNBC PRO

Shares of Teladoc fell more than 2% in extended trading. The company also announced its first-quarter results after market close, reporting revenue of $629.4 million, down 3% year-over-year. Teladoc reported a net loss of $93.0 million, or a 53-cent loss per share.

The UpLift acquisition comes two months after Teladoc announced plans to buy preventative care company Catapult Health, which offers an at-home wellness exam, for $65 million.

Teladoc CEO Chuck Divita has been working to turn the company around after four-straight quarters of declining revenue and an extended slump in the stock price. When Teladoc acquired digital health company Livongo in 2020, it had a combined enterprise value of $37 billion. In early 2022, Teladoc took a write-down of about $6.6 billion tied to the Livongo deal.

Teladoc now has a market capitalization of just over $1 billion. The stock has fallen about 20% this year.

WATCH: Interview with Teladoc CEO

Teladoc Health CEO Jason Gorevic on positive Q1 earnings results



Source

Healthy Returns: What to know about a CDC vaccine panel’s votes against a mercury preservative in flu shots
Health

Healthy Returns: What to know about a CDC vaccine panel’s votes against a mercury preservative in flu shots

Biostatistician and epidemiologist Martin Kulldorff, MD, PhD, and Dr. Mina Zadeh, ACIP Executive Secretary, CDC, look on as people present their information to members of the Advisory Committee on Immunization Practices, as the U.S. Centers for Disease Control and Prevention’s (CDC) advisory panel for vaccines convenes, in Atlanta, Georgia, U.S. June 25, 2025. Megan Varner […]

Read More
Medicaid cuts in Trump’s ‘big beautiful’ bill will leave millions uninsured, threaten rural hospitals
Health

Medicaid cuts in Trump’s ‘big beautiful’ bill will leave millions uninsured, threaten rural hospitals

An aerial view of Valley Health Hampshire Memorial Hospital on June 17, 2025 in Romney, W.V. Ricky Carioti | The Washington Post | Getty Images President Donald Trump’s “big, beautiful bill” would make sweeping changes to U.S. health care, leaving millions of vulnerable Americans without health insurance and threatening the hospitals and centers that provide […]

Read More
Moderna’s flu vaccine shows positive late-stage trial results, paving way for combination Covid shot
Health

Moderna’s flu vaccine shows positive late-stage trial results, paving way for combination Covid shot

The Moderna Inc. headquarters in Cambridge, Massachusetts, on March 26, 2024. Adam Glanzman | Bloomberg | Getty Images Moderna on Monday said its experimental mRNA-based flu vaccine produced a stronger immune response than a currently available shot in a late-stage trial, clearing a path forward for the product and the company’s separate combination flu and […]

Read More